Proton pump inhibitors in the management of GERD

Journal of Gastrointestinal Surgery

Volumn 14, Issue SUPPL.1, 2010, Pages

  Katz, Philip O ^a   Zavala, Stacey ^a  

^a ALBERT EINSTEIN MEDICAL CENTER   (United States)

Author keywords

GERD; Pharmacologic properties; Proton pump inhibitors

Indexed keywords

PROTON PUMP INHIBITOR;

ARTICLE; DRUG EFFECT; GASTROESOPHAGEAL REFLUX; HUMAN; PHYSIOLOGY; STOMACH; STOMACH ACID;

GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HUMANS; PROTON PUMP INHIBITORS; STOMACH;

EID: 77951252484     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-009-1015-3     Document Type: Article

References (29)

1. Locke GR, Talley NJ, Fett SL et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population based study in Olmstead county, Minnesota. Gastroenterology 1997; 112: 1448.
2. Stanghellini V. Relationship between upper gastrointestinal symptoms and lifestyle, psychosocial factors and comorbidity in general population; results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl 1999; 231: 29-37.
3. Fennerty MB. Extraesophageal gastroesophageal reflux disease. Presentations and approach to treatment. Gastroenterol Clin North Am 1999; 28: 861-873.
4. Robinson M. Review article: Current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperdysplasia. Aliment Pharmacol Ther 1999; 13(suppl 5): 5-10.
5. Massoomi F, Savage J, Destache CJ. Omeprazole: a comprehensive review. Pharmacotherapy 1993; 13(1): 46-59.
6. Maton PN. Omeprazole N. Engl J Med 1991; 324(14): 965-975.
7. Bell NJV, Burget D, Howden CW et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51(suppl 1): 59-67.
8. Lew EA. Review article: Pharmacokinetic concerns in the selection of anti-ulcer therapy. Aliment Pharmacol Ther 1999; 13(suppl 5): 11-16.
9. Bensancon M, Simon A, Sachs G et al. Sites of action of the gastric H, K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997; 272: 22438-22446.
10. Klinkenberg-Knol EC, Festen HPM, Meuwissen SGM. Pharmacological management of gastro-oesophageal reflux disease. Drugs 1995; 49: 695-710.
11. Hatlebakk JG, Katz PO, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. APT 2000; 14(10): 1267-1272.
12. Katsube T, Adachi K, Kawamura A et al. Helicobacter pylori infection influences nocturnal gastric acid breakthrough. Aliment Pharmacol Ther 2000; 14(8): 1049-1056.
13. Castell D, Bagin R, Goldlust B, Major J, Hepburn B. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2005; 21(12): 1467-1474.
14. Katz PO, Koch FK, Ballard ED, Bagin RG, Gautille TC, Checani GC, Hogan DL, Pratha VSV. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. Aliment Pharmacol Ther 2007; 25: 197-205.
15. Physicans' Desk Reference. Product information for all proton pump inhibitors, 60th edn. Thomson PDR: Montvale, NJ, 2006.
16. Hatlebakk JG, Katz PO, Kuo B et al. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998; 12: 1235-1240.
17. Howden CW. Vitamin B12 levels during prolonged treatment with proton pump inhibitors. J Clin Gastroenterol 2000; 30(1): 29-33.
18. Laheij RJF, Sturkenboom MCHM, Hassing RJ et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292(16): 1955-1960.
19. Dial S, Alrasadi K, Manoukian C et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ: Can Med Assoc J 2004; 171(1): 33-38.
20. Dial S, Delaney JAC, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile- associated disease. JAMA 2005; 294(23): 2989-2995.
21. Williams C, McColl KEL. Review article: Proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther 2006; 23(1): 3-10.
22. Targownik LE, Lix LM, Metge CJ et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008; 179(4): 319-326.
23. Yang Y-X, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296(24): 2947-2953.
24. Klinkenberg-Knol E, Nelis F, Dent J et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease. Gastroenterology 2000; 118: 661-669.
25. Tutuian R, Katz PO, Castell DO. A PPI is a PPI is a PPI: Lessons from prolonged intragastric pH monitoring. Gastroenterol 2000; 118: A17.
26. Katz PO, Ginsberg GG, Hoyle PE, Sostek MB, Monyak JT, Silberg DG. Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 2007; 25(5): 5617-5628.
27. Richter JE, Kahrilas PJ, Johanson J et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656-665.
28. Castell DO, Kahrilas PJ, Richter JE et al. Esomeprazole (40 gm) compared with lansoprazole (30 mg0 in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97(3): 575-583.
29. Labenz J, Armstrong D, Lauritsen K et al. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther 2005; 21(6): 739-746.